Research Portfolio

Funding Opportunities

Join our Mailing List
Join our mailing list to be notified of new funding opportunities.

Your Email

To receive information about funding opportunities, events, and program updates.



Kevin Scanlon, Ph.D.

Berlex Biosciences # of Grants: 1

Grants

H-Ras Ribozyme Mediated Tumor Suppression of BUX Cells 1995 (Cycle 4) $352,183
Cancer Research Project Awards
Publications

Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme
Periodical: Cancer Research Index Medicus:
Authors: Feng M, Cabrera G, Scanlon K, Curiel D ART
Yr: 1995 Vol: 55 Nbr: 10 Abs: Pg: 2024-2028

Oligonucleotide-mediated modulation of mammalian gene expression
Periodical: FASEB Journal Index Medicus:
Authors: Scanlon KJ, Ohta Y, Ishida H, et al ART
Yr: 1995 Vol: 9 Nbr: Abs: Pg: 1288-1296

Therapeutic applications of ribozymes
Periodical: Pharmacology and Therapeutics Index Medicus:
Authors: Kijima H, Ishida H, Ohkawa T, Kashani-Sabet M, Scanlon KJ ART
Yr: 1995 Vol: 68 Nbr: 2 Abs: Pg: 247-267

Application of ribozymes to cancer gene therapy
Periodical: Cancer Gene Therapy Index Medicus:
Authors: Kashani-Sabet M, Scanlon KJ ART
Yr: 1995 Vol: 2 Nbr: 3 Abs: Pg: 213-223

Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes
Periodical: Journal of Investigative Dermatology Index Medicus:
Authors: Ohta Y, Kijima H, Kashani-Sabet M, Scanlon KJ ART
Yr: 1996 Vol: 106 Nbr: 2 Abs: Pg: 1-6

Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells
Periodical: Nucleic Acids Research Index Medicus:
Authors: Ohta Y, Kijima H, Kashani-Sabet, Scanlon KJ ART
Yr: 1996 Vol: 24 Nbr: 5 Abs: Pg: